RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
Stiolto Respimat (tiotropium bromide and olodaterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD). Stiolto Respimat can cause side effects that range from mild to ...
In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results